Cipher Pharmaceuticals Inc. (CPH) Earnings Call Transcripts

Cipher Pharmaceuticals Inc.'s Latest Earnings Call - Q1 FY2026

In Q1 2026, Cipher Pharmaceuticals reported total net revenue of $12.5 million, a 4% increase year-over-year, driven primarily by growth in licensing revenue and the U.S.-based Natroba business. Adjusted EBITDA rose to $7.7 million, reflecting a 25% increase from the prior year. Management highlighted strong cash generation, having fully repaid a $5 million revolving credit facility, and announced a renewed NCIB allowing for the repurchase of up to $1.5 million in shares, signaling confidence in capital allocation. No changes to guidance were provided, but management indicated ongoing efforts to expand the Natroba business and pursue strategic acquisitions.

Reported metrics

Guidance from management

Management did not provide specific numerical guidance for future quarters but indicated ongoing efforts to expand the Natroba business and pursue strategic acquisitions.

What management said

Max, Craig Mull here. I'm with Ryan Mailling, who is part of our presentation and Bryan Jacobs, who's the President of the U.S. Operations. I'm going to turn the question to Bryan.

Yes, that's a good question. We expect the audience coming through that will largely be commercial volume and we do realize a higher net price on sales of commercial. So -- and that's -- that would be on the authorized generic Spinosad. So we do realize a higher net price on Spinosad today. And as we drive further volumes through that, that are commercial focused, we think that will only benefit net price going forwa...

What analysts pressed on

Analysts expressed concerns regarding the effectiveness of the direct-to-consumer sales model, particularly in early quarters. There were inquiries about potential pricing dynamics as this model scales, and whether the company would consider upsizing its credit facility to support larger business development targets.

Main topics on the call

• Revenue Growth — Cipher's total net revenue for Q1 2026 was $12.5 million, up from $12 million in Q1 2025, attributed to increased licensing revenue and growth in the Natroba business. Management stated, "The increase was attributable to...
• Adjusted EBITDA Increase — Adjusted EBITDA for Q1 2026 reached $7.7 million, a 25% increase year-over-year. This growth was driven by higher licensing revenue and reduced selling, general, and administrative expenses, as noted by management: "The ...
• Debt Repayment — Cipher fully repaid its $5 million revolving credit facility during the quarter, with management emphasizing, "We have repaid the full $40 million of debt that was drawn upon to partially fund this acquisition." This hig...
• Natroba Business Development — Management is actively pursuing a direct-to-consumer sales model for Natroba, launched in March 2026. Bryan Jacobs stated, "We plan on doing a lot of digital marketing... which is not only going to benefit direct-to-cons...

Read the full Cipher Pharmaceuticals Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 30 Cipher Pharmaceuticals Inc. earnings call transcripts on record, spanning March 26, 2020 to August 12, 2026. Based on this history, Cipher Pharmaceuticals Inc. reports quarterly. The most recent call on file is dated August 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CPH

Exchange

TSX

Country

CA

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

30

First call

March 26, 2020

Most recent

August 12, 2026

Reporting cadence

quarterly